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Abstract: The aim of our study was to assess the clinical effectiveness of topical adipose derived
stem cell (ADSC) treatment in laser induced corneal wounds in mice by comparing epithelial repair,
inflammation, and histological analysis between treatment arms. Corneal lesions were performed
on both eyes of 40 mice by laser induced photorefractive keratectomy. All eyes were treated with
topical azythromycin bid for three days. Mice were divided in three treatment groups (n = 20),
which included: control, stem cells and basic serum; which received topical treatment three times
daily for five consecutive days. Biomicroscope assessments and digital imaging were performed by
two masked graders at 30, 54, 78, 100, and 172 h to analyze extent of fluorescein positive epithelial
defect, corneal inflammation, etc. Immunohistochemical techniques were used in fixed eyes to assess
corneal repair markers Ki67, α Smooth Muscle Actin (α-SMA) and E-Cadherin. The fluorescein
positive corneal lesion areas were significantly smaller in the stem cells group on days 1 (p < 0.05),
2 (p < 0.02) and 3. The stem cell treated group had slightly better and faster re-epithelization than
the serum treated group in the initial phases. Comparative histological data showed signs of earlier
and better corneal repair in epithelium and stromal layers in stem cell treated eyes, which showed
more epithelial layers and enhanced wound healing performance of Ki67, E-Cadherin, and α-SMA.
Our study shows the potential clinical and histological advantages in the topical ADSC treatment for
corneal lesions in mice.
Keywords: adipose derived stem cells; corneal wound healing; stem cell therapy; lipoaspirate; corneal
re-epithelization
1. Introduction
The cornea provides a protective barrier and clear optical pathway for the visual system.
This avascular and transparent structure is composed of three layers, which include the outer most
non-keratinized stratified epithelium, stroma, and single-layered endothelium. Most corneal diseases
and trauma involve the epithelium and stroma and include immune disorders, chronic inflammation,
infection, iatrogenic procedures (i.e., laser refractive surgery), etc. These ocular disorders tend to cause
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severe inflammation, persistent epithelium defects, neovascularization, conjunctivalization, persistent
corneal opacities, and scarring, which can all lead to permanent vision loss [1–3].
The most common intervention for restoring corneal clarity and function is full thickness
penetrating or lamellar keratoplasty. However, there are great limitations related to little availability of
donor tissue and costs and complications related to surgery (i.e., graft failure, chronic inflammation,
numerous follow-up, etc.). Alternative surgical techniques include amniotic membrane transplantation
and conjunctival limbal autograft from the healthy fellow eye, but surgical outcomes and limitations
are similar to keratoplasty [1]. Studies have shown that autologous serum [4] autologous plasma rich
in growth factors [5,6] and other novel topical treatments [7,8] can be beneficial in patients with various
ocular surface disorders due to inflammation, severe dryness, and persistent epithelial defects [4–6].
However, long-term clinical efficacy multicenter data and standardized preparation protocols are
lacking. Moreover, therapeutic effects tend to be superficial, limiting and symptomatic involving the
corneal epithelial and not directed on lesion induced stromal scarring and damage.
In the past decade, stem cell therapy has been proposed in almost every branch of medicine, ranging
from cardiology, neurology, plastic surgery, dentistry, etc. [9–12] Similar to bone marrow derived stem
cells, numerous studies have shown that adipose derived stem cells (ADSC) are pluripotent and have
the capability of differentiating into multiple mesodermal cell lineages expressing specific markers
and proteins [12–14]. The interest in ADSC has greatly increased considering that it is easy to obtain
large quantities of autologous tissue in a rapid minimally invasive liposuction procedure that requires
only local anesthesia. Moreover, ADSC are extremely more abundant in adipose tissue than MSC in
bone marrow [15].
Numerous studies based on ADSC obtained from processed human lipoaspirate to treat corneal
lesions in various animal models have shown stem cells to be able to differentiate and produce corneal
specific proteins, thus enhancing wound healing and maintaining transparency [16], while providing
inhibition of inflammation [3] and angiogenesis [2]. ADSC can be placed in corneal stromal pockets.
However, surgical manipulation of cells and of the host cornea can be potentially damaging and may
not be of potential clinical use in a clinical setting.
Topical stem cell therapy may be of potential clinical use considering that ADSC are abundant,
cost efficient, multipotent, non-invasive, and beneficial in various phases of wound healing including
cellular remodeling, changes to tear composition, cell migration, proliferation, epithelial reattachment,
and stromal remodeling. Our previous study reported the topical use of ADSC in chemically
induced corneal lesions in rats [17]. These preliminary results showed that stem cell treated eyes had
significantly smaller epithelial defects at each time point, with better and faster re-epithelization and
less inflammatory response compared to other treatment arms. The ADSC group seemed to show
improved corneal wound healing. However, a small number of animals with chemically induced
lesions in a brief time were considered in the treatment and in the clinical assessment to provide a
semi-quantitative assessment of data. The purpose of our current study was to assess a greater number
of eyes over a longer time period using a reproducible laser-induced corneal wound in mice in addition
to provide a comparison of epithelial repair, stromal haze, inflammation, and quantitative histological
analysis between treatment groups.
2. Material and Methods
2.1. Animals
Forty black male mice C57BL/6 (30–40 g) purchased from Charles River Laboratories (Barcelona,
Spain) were used in the experiments. Animals were housed with a 12-h light–dark cycle with ad
libitum access to food and water. Animal care and experiments were carried out in accordance
with the guidelines of the Spanish Ministry of Health for Animal Care (RD 53/2013) and European
Commissions (2003/65/EC).
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Prior to induction of lesion and treatments, mice were anesthetized by intraperitoneal injection
of 80 mg/kg ketamine hydrochloride (Imalgène 500, Merial, Lyon, France) and 5 mg/kg xylazine
hydrochloride (Rompun, Bayer HealthCare, Kiel, Germany). Topical anesthesia was induced by 0.4%
oxibuprocain eye drops (Novesina, Novartis, Varese, Italy). Animals were euthanized with an overdose
of sodium pentobarbital (Dolethal, Vétoquinol, Lure, France) and verified by cervical dislocation.
2.2. Isolation and Preparation of Adipose Derived Stem Cells
Human subcutaneous abdominal adipose tissue was obtained from healthy patients (aged
35–64 years) undergoing elective lipoaspiration surgery with informed oral and written consent under
a protocol approved by the Institutional Review Board (IRB) of the University of Udine, in accordance
with the guidelines of the Tenets of the Declaration of Helsinki. Patients were screened and resulted
negative for HIV, hepatitis B and C virus, and syphilis.
Isolation, preparation, flow cytometry, immunofluorescence, and multilineage differentiation of
ADSC have been reported in our previous studies [12,17,18].
For the in vivo experiment, we employed ADSC obtained from a 35 year old female patient, at the
third passage in culture, in their undifferentiated state.
2.3. Blood Serum
Human serum was prepared in accordance to the Azienda Ospedaliero Universitaria Santa Maria
della Misericordia protocol [17]. In brief, 500 mL of whole blood from one healthy young male
donor (45 years old) was collected into sterile 9 mL tubes after written informed consent. The patient
was screened and resulted negative for HIV, hepatitis B and C virus, and syphilis. The containers
were left standing in an upright position to ensure clotting for at least 30 min at room temperature,
then centrifuged at 2000× g for 10 min. The supernatant serum was removed under sterile conditions
in a laminar flow hood with sterile disposable syringes. The vials were frozen and left to thaw for
24 h before treatment. In accordance to our hospital protocols on clinical treatment for severe dry eye
syndrome, we used undiluted whole serum.
2.4. Laser Induced Corneal Wound
After intraperitoneal and topical anesthesia, corneal lesions were performed on both eyes of
40 mice by laser induced photorefractive keratectomy (PRK) [19]. To induce the epithelial and
stromal laser lesion, each eye was placed under a Wavelight Allegretto Wave PR-020407 excimer laser
(Wavelight GmbH, Alcon, Erlangen, Germany). The PRK ablation parameters included a diameter of
2 mm to the central optic zone and a total depth of 45 µm to induce a uniform lesion affecting both
epithelium and stroma. The laser began nasally and progressed temporally.
2.5. Treatment Regimen
All animals were treated with topical eye drops of azythromycin 1.5% (Azyter, Laboratoires
Thea, Clemrmont-Ferrand, France) for antimicrobial prophylaxis two times daily for three days after
lesion [19]. Eighty eyes of 40 mice were divided in four treatment groups (n = 20 eyes per group),
which included control, stem cells, basic serum, and plasma rich in growth factor (PGRF). Data from
the PGRF (not shown) were intended and collected for a different ongoing study. Control eyes received
only antibiotic eye drops. The other 3 groups also received topical treatment applied three times
a day for five consecutive days. Topical drops were administered with a delay of at least 5 min
between applications for multiple treatment regimens. Stem cell topical eye drops were prepared daily
with 1 × 105 cells suspended in 25 µL HBSS/treatment [16]. The basic serum group received topical
application of 25 µL of 100% human serum.
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2.6. Ocular Surface Evaluation
Upon topical anesthesia, each treated eye was examined with a stereo biomicroscope before
application of topical treatment at 30, 54, 78, 100, and 172 h after lesion (also referred to in this study as
day 1, 2, 3, 4, and 7, respectively). This was done at each time point to assess corneal inflammation,
opacities, and other anterior surface complications (i.e., infection, perforation, etc.). Fluorescein sodium
solution (Colircusí Fluoresceína, Alcon Cusí, Barcelona, Spain) was used to evaluate the degree of the
corneal epithelial defect. Each animal’s anterior segment was photographed with a Leica S6D stereo
microscope (6.3:1 zoom and 15.0× magnification) equipped with a Leica EC3 digital camera (Leica
Microsystems, Wetzlar, Germany) with and without fluorescein at each clinical assessment. The defect
area was determined by the fluorescein positive remaining area under blue light (1 mm = 240 pixels)
using ImageJ 1.45a software (National Institutes of Health, Bethesda, MD, USA). Based on anterior
segment visualization of pupil, iris and the presence of corneal vessels with stereo biomicroscopy at
each examination time point. The analysis was performed independently by two masked graders.
2.7. Histological Examination
Eyes were fixed in Somogyi’s fixative without glutaraldehyde, rapidly frozen in liquid nitrogen,
and preserved in OCT compound. The specimens were cut into 5 µm-thick tissue sections with a
cryostat and subjected to immunofluorescence techniques. Sections were examined under fluorescence
microscopy. With regards to the 33 mice of the 40 animals (66 eyes) included in the analysis, 32 eyes of
16 animals were enucleated after 78 h (day 3), while the remaining 34 eyes of 17 mice were enucleated
at the end of the study at 172 h (day 7) post-lesion. The details regarding the histological preparation
and assessment are reported in the Appendix A.
For immunofluorescence analysis we used antibodies to Ki67 (proliferation; 1:500; Abcam,
Cambridge, UK), α-SMA (myofibroblast transformation; 1:200; Abcam), E-cadherin (assembly of
epithelial cells; 1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Further details regarding the
antibodies used in our study have been reported in the Appendix A under the heading “Histological
examination” on page 14, lines 532–575.
3. Statistical Analysis
Normality of the data distribution was assessed with the Kolmogorov-Smirnov test. Data were
expressed as median ± standard deviation. Differences of the data amongst groups were analyzed
with SPSS 20.0 (SPSS Inc., Chicago, IL, USA) for Windows program using Kruskal-Wallis and Friedman
test. Multiple comparisons were performed with Dunnett’s test. A p value of < 0.05 was considered to
be statistically significant.
4. Results
4.1. Clinical Outcomes
The PRK lesion was performed uneventfully in all mice eyes. Immediately after the laser ablation, the
treated areas showed a whitish uniform, hazy appearance. There were no signs of neovascularization
or perforation in all eyes. Three animals (#24, 29 & 39) died of hypothermia at 30 h after anesthesia,
and four animals (#6, 12, 38 & 28) were found dead in the cages (probably due to natural causes) before
the endpoint on the 7th day. A total of 33 of 40 animals (66 eyes) were considered in the statistical
analysis: 18 stem cell treated eyes, 15 basic serum eyes, and 17 control eyes. Of these, 16 (32 eyes)
underwent treatment for three days and sacrificed at 78 h, and the remaining 17 animals (34 eyes)
completed the five-day treatment regimen and then sacrificed at 172 h.
Partial re-epithelization was seen in all mice eyes at the first time point at 30 h. All eyes were
completely re-epithelized by 100 h (Table 1a and Figure 1). On the first day, the fluorescein positive
corneal lesion area was significantly smaller in the stem cells groups than the control eyes (Table 1a,
Figures 1 and 2; p < 0.05); on the second day, it was significantly larger in the controls, yet comparable
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between stem cell and serum treatment groups (Table 1a, Figures 1 and 2; p < 0.02). No differences
were found amongst groups on the other days.
Table 1. (a) Median fluorescein positive corneal lesion area (mm2) in mice for each group over time.
(b) Number Ki67 cells in the peripheral and central post-lesion corneal epithelium and stroma in the
different treatment groups at day 3 and day 7 after lesion (mean of total number of cells in three sections
per corneal sector).
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Figure 1. Intragroup comparisons of median epithelium defect area over time for each treatment
group in the mice eyes. * = statistically significant difference between stem cells and control groups;
ˆ = statistically significant difference between controls and the other groups.
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Figure 3. Fluorescein po itive areas at each time for animals # 1, 2, 3, and 17. For intraindividual
comparisons, the right eye (red squares) of each mouse was treated with stem cells and the left eye
(blue triangles) was treated with the control regi en. The stem cell eyes tended to show better epithelial
wound healing than the control eyes in the first three days with smaller fluorescein areas and faster
total re-epithelization.
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Qualitative histology assessments were performed in 27 eyes of 15 mice eyes at 78 h (day 3) after
lesion (10 control, 8 stem, 9 basic serum) and 28 eyes of 15 mice eyes at 172 h (day 7) after lesion
(8 control, 10 stem, 10 basic serum).
4.2. Histological Outcomes
With regards to the epithelium histological assessment after three days, the stem cell group
showed a slightly increased number of epithelial cell layers (Figures 4 and 5). There were three layers
of epithelial cells in the peripheral region of the damaged cornea, while about four layers of cells
in the central post-injured area. The number of Ki67 cells in the peripheral epithelium was similar
amongst groups, however, the stem cells treated eyes showed less of these actively replicating cells in
the epithelium, yet more in the stroma underlying the lesion when compared with the other groups
(Table 1b). E-Cadherin protein accumulated in the basal cell layer of the epithelium and was present in
the cytoplasm (Figure 5). This localization suggests that the epithelium was not stabilized and was
still involved in a reorganization process [20–22]. In the control eyes, there were only three layers
of epithelial cells and a slightly less number of Ki67+ cells in the peripheral epithelium (Table 1b).
The E-Cadherin pattern was similar to that described in the stem cell treated eyes (Figure 5). In the
basic serum eyes, there were 5 to 6 layers of epithelial cells and a higher number of Ki67+ cells across
the extension of the epithelium. The E-Cadherin pattern was diffuse in the basal cells of the epithelium,
similar to the stain observed in the other groups.
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Figure 4. I ages of Ki67 positive cells (in red) in the central epitheliu of ound healing corneas
treated with adipose-derived ste cells ADSC for three days (A) co pared to the control eyes (B).
Both groups showed a high number of proliferating cells in the basal cell layer of the regenerating
epithelium (arrows). Note a slightly higher level of organization in stem cell treated cornea. Some
proliferating cells could be found in the stroma (asterisks) (Scale bars: 40 µm).
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Fig re 5. Corneal epithelium wound healing after three days assesse with E-Cadherin immunostaining.
(A) represents an eye treated with ADSC. E-Ca herin (marked in red) appeared to be distributed in the
asal cell layer of the epithelium and accumulated in the cytoplasm. Elongated irregular processes
could be seen in the stroma; some cells pre ented E Cadherin staining; (B) represents a co trol eye,
which showed a similar pattern f distribution of E Cadherin staining in the cor ea. Nuclei ar
unterstain d with DAPI (in blue). Note the difference in the number of layers between stem cell
tr ated group and untr ated corneas (Scal bar 40 µm).
With regards to the stromal histology at three days, all eyes showed E-Cadherin-positive cells
indicating the presence of migratory elements in the stroma, probably involved in reparative processes.
Moreover, a small number of myofibroblasts (α-SMA positive profiles) were found in the stromal under
the epithelium in the lesion area. These myofibroblasts were more frequent in the control corneas
when compared to those found in the basic serum treated eyes. These myofibroblasts were scarce and
not frequently seen in the stem cell treated eyes (Figure 6a).
After seven days of lesion, the stem cell treated eyes showed epithelium that was similar to
uninjured epithelium, composed of 4 to 5 layers of uniform and perfectly structured epithelial cells
(Figure 6b). E-Cadherin protein was localized at the periphery of epithelial cells, similar to what
is normally found in healthy uninjured epithelium, thus indicative of a stabilization of the corneal
regenerating epithelium [22]. The number and distribution of proliferating Ki67 positive cells were
similar to that measured in normal mouse corneal epithelium. The control eyes showed the same
structure of epithelium; however, there appeared to be at least one additional layer and more Ki67
positive cells (Table 1b, Figure 7). The basic serum treated eyes showed about 5 to 6 layers in the
epithelium and a higher number of Ki67 positive cells (Table 1b).
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Figure 6. (a) ADSC treatment (A) seemed to retard the onset of myofibroblast appearance when
compared to the controls eyes (B) during the initial stages of the wound healing process (three days
after injury). There tended to be scarce or no yofibroblasts in the stro a in the ADSC treated eyes;
only a diffuse staining for α-S A (in red arrows) was visible in the basal cells of the central epitheliu
(A). In contrast, several α-S + yofibroblasts (sho n as elongated cells stained in red asterisks)
ere present in the upper stroma of the control eyes (Scale bars: 40 µm). (b) E-Cadherin staining
(in red) 7 days after injury. E-Cadherin appeared to be located bordering the epithelial cells and
rarely accumulated in the cytoplasm in the ADSC treated eyes (A). The control corneas showed a
different staining pattern for E Cadherin, which accumulated in the cytoplasm of the epithelial cells (B).
A similar location of epithelial E-Cadherin was found in the basic serum treated eyes, ic te e t
l t i t e cytoplasm of the basal cells (C). There also appeared to be more E-Cadherin+ cells in
the stroma of the basic serum treat d yes. (Scale bar 40 µm).
The stromal histology after seven days (Figure 7) showed that the stem cell treated had little or no
E-Cadherin positive elements in the stroma. The E-Cadherin positive elements, however, appeared to
be abundant in the basic serum treated eyes and control eyes, which can be indicative of migratory
events in the stroma. After seven days, there was a significant reduction in the quantity of α-SMA+
myofibroblasts in stem cell treated group (4.09 ± 0.48 cells) compared to control (10.85 ± 0.76 cells;
p < 0.001) and, to a lesser extent, compared to basic serum group (6.27 ± 0.65 cells; p < 0.05).
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5. Discus ion
Similar to our previous studies, ADSC were obtained from human adipose tissue aspirates
following a protocol optimized for the isolation and in vitro expansion of human multipotent adult
stem cells [12,17]. ADSC expressed the pluripotent state-specific transcription factors Oct-4, Nanog
and Sox 2 [12,17]. ADSC highly expressed CD90, CD105, CD73, however, were mainly negative for the
hematopoietic markers CD34 and CD45. These cells displayed multipotency. Further details regarding
ADSC are reported in the Appendix A. Our results show that ADSC seem to enhance corneal wound
healing induced by laser ablation when compared to traditional topical therapy.
In accordance to our previous study based on chemical induced corneal lesions in rats [17],
the percent of epithelium fluorescein positive damage in eyes treated with stem cells (with or without
serum) was smaller at each time point, which was statistically significant when compared to the control
mice eyes (Table 1a). Stem cell treated eyes reached complete epithelium closure faster than the control
eyes (Figure 1). The results showed statistically smaller lesions after day 1 in the stem cell group,
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which was comparable to the basic serum treated eyes but less than that observed in the control group
on days 2 and 3 (Table 1a, Figures 1 and 2).
With regards to the mice histological data, the presence of more layers of epithelial cells in the
early stages of repair in the stem cell treated group compared to the control eyes could be related to
an improvement in the re-epithelization of the corneal surface after injury. The epithelium under the
lesion had a smaller number of Ki67 actively replicating cells in the stem cell eyes, yet the stroma
appeared to have significantly more than the other groups (Table 1b), which may be indicative of earlier
stromal repair and post-mitotic epithelium layer reformation in this group at three days. Although
these epithelial layers covered the entire corneal surface, these cells appeared to be undergoing
reorganization during the initial period after lesion, as deduced by the elevated rate of proliferation
of basal epithelial cells in the central region of the cornea and the localization pattern of E-Cadherin
protein in the epithelium [21,22]. E-Cadherin did not appear to be distributed in the periphery of
epithelial cells, as expected in stable uninjured epithelium; however, it mostly accumulated in the
cytoplasm of basal epithelial cells. This location of E-Cadherin suggested an ongoing reorganization
process of the epithelial layers [20–22].
Although all eyes exhibited complete re-epithelization macroscopically after seven days, the
histological evaluation showed that the epithelium of individuals treated with stem cell contained four
or five layers, which is the number of layers normally found in uninjured mouse corneal epithelium.
The number of dividing cells (Ki67+) in the central region was very low, which resembled a normal
cornea with a well-established epithelium structure. The cytoarchitecture of the epithelium was that
of a normal epithelium, showing cuboidal cells in the basal layer, with a few layers of low cuboidal
cells positioned on top, followed by 1–2 outer sheets of flattened wing cells. E-Cadherin appeared
to be located externally bordering epithelial cells and was observed in all layers. In comparison,
the control eyes had at least one additional layer of epithelial cells, which may be indicative of an
incomplete or altered repair process. The eyes treated with the blood derivatives PRGF (data not
shown) and basic serum showed five to six layers of epithelial cells, which may be indicative of an
ongoing re-epithelization and possible delay in the cessation of cell proliferation in the central region
of the cornea, as seen with the presence of numerous Ki67+ cells.
The stroma of mice eyes treated with stem cells had a notably lower density of myofibroblasts
(α-SMA+ elements) compared with control and basic serum eyes at both three and seven days, which
may be related to the slightly better corneal transparency and lower haze in the stem cell eyes
(based on a qualitative comparative analysis between groups, data not shown) [23–27]. E-Cadherin+
cells were not found in the stroma of stem cell treated eyes and controls after seven days, yet were
abundant in the PRGF and serum treated eyes. The lack of E-Cadherin+ cells can be indicative of
a stabilization of the stromal cytoarchitectural organization. In contrast, the stroma of the blood
derived treated groups continued to have reorganizations events and mobility of cellular elements
in the stroma. The physiological roles of ADSC are diverse and promising in tissue regeneration and
wound healing [13,14,28]. ADSC obtained from lipoaspirate have been shown to meet the minimal
set of 4 criteria proposed by the Mesenchymal and Tissue Stem Cell Committee of the International
Society for Cellular therapy [29] used to define functional human MSC [12,13,18,30] In addition to their
extensive proliferation potential and multilineage differentiation, ADSC can interact and affect the
immune system response to injury, by the down-regulation of proinflammatory factors and production
of several trophic factors [23,31,32]. Several reports have shown the immunoregulatory properties of
MSC, which include the inhibition of T-cells [33], increase in tumor necrosis factor (TNF) from dentritic
cells [34], increase in regulatory T-cells [34], block of antigen producing cell maturation [35], increase
in immunosuppressive cytokine interleukin (IL)-10 and TNF-β and decrease in IL-2 [2]. The endocrine
function of adipose tissue is evident through the secretion of numerous growth factors (GF) like
epidermal GF, vascular endothelial GF, basic fibroblast GF, keratinocyte GF, and platelet-derived
GF [30].
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There are limited studies in current literature regarding the use of ADSC in ocular surface
and stromal wound healing [36–39]. Arnalich-Montiel showed that human ADSC could regenerate
into corneal tissue in situ when inserted in a laser induced intrastromal corneal pocket in a rabbit
model [16]. The transplanted cells appeared to be safe, maintained corneal transparency and caused
no immune reaction [40]. The transplanted multipotent stem cells acquired similar characteristics to
keratocytes [41]. Studies have shown that topical application of stem cells are easy, and may prove to
be clinically acceptable and effective in acute phases [42,43].
The presence of corneal limbal stem cells (LSC) was first discovered in the late 1980’s [44]. These
slow-cycling subpopulation of epithelial basal cells located in the peripheral limbus of the cornea
were found to have a substantial proliferating capacity. Autologous and allogenic LSC transplants are
surgical option [45], however, donor tissues are limited and autologous transplants may give rise to
iatrogenic damage to the healthy fellow eye or at times the fellow eye is not healthy. Recent studies
have reported the presence of MSC in the human limbal biopsies having similar immunophenotype
and immunocytochemical markers to those present in bone marrow derived MSC [46].
With regards to the clinical use of ADSC for ocular surface wounds in humans, only a single
case report has been published by a group in Greece [47]. A young male underwent an experimental
treatment involving topical application of autologous ADSC, which was obtained by lipoaspiration
of subcutaneous adipose tissue from the lumbar area. The ADSC were isolated from the lipoaspirate
and applied to the bottom of the ulcer, followed by closure of the lid with a pressure eye patch for
24 h. Corneal healing was observed after 11 days. At six months after treatment, the patient still
did not require surgery, visual acuity was improved to 20/40, central corneal thickness was 476 µm,
and corneal transparency improved with mild residual anterior stromal opacification.
6. Conclusions
Our mice experiments based on a laser-induced lesion confirmed that stem cell treated eyes had
significantly smaller epithelial defects at each time point, with better and faster re-epithelization and
less inflammatory response compared to other treatment arms, which was already reported in our
preliminary rat study based on a chemical induced lesion model. Literature in this field is limiting,
thus additional studies using a different animal model and different type of lesion was proposed in
this study to confirm preliminary experiments and report additional data. Our mice experiments were
based on a larger group of animals assessed for a longer follow-up compared to our preliminary rat
studies. Our study adds to the limiting literature currently available in this field by confirming the
biosafety, immunogenicity, and potential clinical and histological advantages in using this mode of
stem cell treatment. Future studies involve the assessment of epithelial recovery, inflammation, corneal
haze, and quantitative histological assessments compared in different treatment arms. Although the
exact mechanisms are not known, these cells are multipotent and have the potential to differentiate
toward a keratocyte stromal lineage and therefore theoretically appear to be a promising therapeutic
alternative and advantageous compared to treatments currently utilized in clinical practice. Most
studies have shown ADSC to be promising in animal models, which can serve as a great stepping
stone in addressing the topical therapeutic use of stem cells in humans.
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Appendix A
Appendix A.1. Animals
Our decision to use both eyes was not solely based on a cost issue but based on a similar
experimental model used in our previous study published in Current Eye Research [17]. This was done
in accordance to the 3R statement of the European Community (reduce, replace, refine) that encourages
the use of fewer experimental animals, and to compare treatments on the same animals to reduce
inter-animal variability, thus both eyes were also used in the experiment. In addition, we obtained the
approval of the Animal Ethical Committee of the University of Oviedo (Spain).
Appendix A.2. Histological Examination
Eyes were fixed in Somogyi’s fixative without glutaraldehyde for 3 h, cryoprotected overnight
in 30% sucrose solution, embedded in OCT compound and frozen in liquid Nitrogen. The entire
frozen eyeball was placed on a cryostat chunk and oriented to obtain transversal sections of the cornea.
Cryostat sections with a thickness of 5 µm were collected on Superfrost microscope slides (Thermo
Scientific, Rochester, NY, USA) and stored frozen.
For each eye, three selected histological sections in the central region of the injured cornea were
chosen to demonstrate each marker used to evaluate the quality of corneal repair, which included:
1. Polyclonal antibody against Ki67 produced in rabbit (Abcam, Cambridge, UK): This antibody is
present in the nuclei of actively dividing cells and can be used as a measure of the number of
proliferating cells in a repairing process [48].
2. Polyclonal antibody against α Smooth Muscle Actin (α-SMA) produced in rabbit (Abcam,
Cambridge, UK): The α-SMA presenting cells are identified as myofibroblast during the wound
healing process [24,25,49].
3. Polyclonal antibody against E-Cadherin produced in rabbit (Santa Cruz Biotechnology,
Santa Cruz, CA, USA): The E-Cadherin protein locates normally bordering epithelial cells, thus
allowing a visualization of the cytoarchitecture of a multilayered epithelium [20,21].
Fluorescent immunohistochemical techniques were used to assess these markers. Selected
cryosections were carefully thawed in a water bath; slides were placed in a humidity chamber and
washed three times in PBS (Phosphate Buffered Saline) with Triton X-100 (0.03%). A brief incubation
with a blocking medium (1% bovine serum albumin and 10% normal goat serum; Vector Laboratories,
Burlingame, CA, USA) was added to avoid nonspecific binding of the secondary antibody. The blocking
medium was then removed by washing the slides three times with PBS with Triton X-100 (0.03%).
The sections were incubated overnight at 4 ◦C with the appropriate primary antibody at a specific
dilution (Anti-Ki67 at 1:500; Anti-αSMA at 1:200; and, Anti-E-Cadherin at 1:100). Sections were then
washed again three times in PBS and incubated with a fluorescent secondary antibody (anti-rabbit
Alexa Fluor 594 raised in goat, Molecular Probes, Grand Island, NY, USA) in a dilution of 1:500 for
2 h at room temperature in the dark. Three additional washes were then used to eliminate the excess
of fluorescent antibody. Nuclei were counterstained with 2 µg/mL 4′,6-diamidino-2-phenylindole
dihydrochloride (DAPI; Molecular Probes, Grand Island, NY, USA) for 10 min and slides were mounted
with Dako fluorescence mounting medium (Dako, Glostrup, Denmark) and coverslips. Slides were
then identified and encoded with a numerical system and stored at 4 ◦C.
The analysis of the wound healing parameters was performed on histological images using a
Leica DM6000 microscope equipped with epifluorescence using a 20× objective (numerical aperture
0.45) and AF6000 software (Leica Microsystems, Wetzlar, Germany). Measurements were performed
in a semiautomated manner using ImageJ 1.45a software (National Institutes of Health, Bethesda, MD,
USA). Two independent masked observers performed the analysis. Data were collected and decoded,
and statistical analysis was performed using InStat 3.1a software (GraphPad Software Inc., La Jolla,
CA, USA).
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Appendix A.3. Adipose-Derived Stem Cells (ADSC)
Human subcutaneous abdominal adipose tissue was obtained from thee healthy female patients
(aged 35, 52, and 64 years) undergoing elective lipoaspiration surgery. ADSC used in the treatment
group, however, came from a single healthy donor (youngest female aged 35 years) and were employed,
at the third passage in culture, in their undifferentiated state. Cells were characterized in accordance to
the study reported by Domenis et al. in 2015 [29]. Specifically, cells satisfied the minimal criteria of ISCT.
Moreover, they were checked for additional markers, such as the expression of pluripotent state-specific
transcription factors. Although we are aware that a certain degree of controversy surrounds this latter
feature, Chih-Chien Tsai et al. [50] has shown that Oct-4 is not only expressed but also required for
MSC self-renewal. Additionally, other independent groups showed the expression of these markers in
MSC [51,52].
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